Supervisor View Full Details 2nd

• genetics, genomics and molecular biology
• cancer/oncology
• bioengineering/medical devices

• Medicine
• Surgery
• Pathology
• Public Health
• Sports and Exercise Medicine

• Clinical Trials
• Health Informatics
• Hospice and palliative medicine
• Oncology
• Radiology
• Other

Prostate cancer clinical and translational research, particularly advanced radiotherapy, stereotactic, brachytherapy, drug-radiation combination studies and biomarkers. I am a clinical-translational academic clinical oncologist, I work with a very large, collaborative research group focussed on prostate cancer. We comprise clinicians, medical physicists, radiobiologists, molecular biologists, pathologists and bioinformaticians. I collaborate closely with several institutions, particularly, University of Manchester, University of Toronto, Institute of Cancer Research and Royal Marsden, Trinity College Dublin and DIT.

Recent key abstracts or papers:

Jain S, Lyons C, Walker SM, et al. A metastatic biology gene expression assay to predict the risk of distant metastases in patients with localized prostate cancer treated with primary radical treatment. Journal of Clinical Oncology 2017; 35(6_suppl): 11.

Nicolae, A, Morton G, Chung H, Loblaw A, Jain S, Mitchell D, Lin L, Helou J, Heath E, Ravi A. Evaluation of a machine-learning algorithm for treatment planning in prostate Low-Dose-Rate brachytherapy. IJROBP. 2016 (in press 2017).

Chen, R. C., R. B. Rumble, D. A. Loblaw, A. Finelli, B. Ehdaie, M. R. Cooperberg, S. C. Morgan, S. Tyldesley, J. J. Haluschak, W. Tan, S. Justman, And S. Jain. "Active surveillance for the management of localized prostate cancer (Cancer Care Ontario guideline): American Society of Clinical Oncology Clinical Practice guideline endorsement." Journal of Clinical Oncology (2016). J Clin Oncol. 2016;34(18):2182-90.

Mateo J, Carreira S, Sandhu, S, Mossop M, Perez-Lopez R, Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Paulding C, Seed G, Jain S, Hussain S, Jones R, Elliott T, McGovern U…Knudsen K, Feng F, Chinnaiyan A, Hall E, De Bono J. DNA repair defects and PARP inhibition in Metastatic Prostate Cancer. New England Journal of Medicine (NEJM) October 2015.

Klotz L, Vesprini D, Sethukavalan, P, Jethava V, Zhang L, Jain S, Yamamoto T, Mamedov A, Loblaw A. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. Journal of Clinical Oncology (JCO) 2015 33(3) 272-277.

An ICATs clinician PhD would become an integral part of our large prostate cancer research group. There is flexibility to tailor a research project to the interests of the applicant but the successful applicant would be clinically active, learning new skills that may include advanced radiotherapy, prostate brachytherapy, gold fiducial insertion, SpaceOAR insertion and transperineal biopsies. They would be assigned a clinical trial with translational components, examples include, stereotactic radiotherapy in prostate cancer, inhibitors of apoptosis (IAP) combined with radiotherapy in advanced prostate cancer, CXCR2 inhibition combined with enzalutamide in metastatic castrate resistant prostate cancer, exercise studies in patients with metastatic prostate cancer receiving chemotherapy. Translational elements could include close collaboration with medical physics on dosimetric or radiomic features of prostate imaging, molecular biology (serial primary prostate cancer tissue samples) or bioinformatics (we have large datasets with full clinical annotation and gene expression data).